XenoGesis and Juniper Pharma Services strengthen alliance with investment in GastroPlus™

XenoGesis and Juniper Pharma Services strengthen alliance with investment in GastroPlus™
October 17, 2017 suecarr

XenoGesis and Juniper Pharma Services have extended their strategic alliance around their Enabling Technologies Rapid Screen through the addition of the gold standard PBPK modelling and simulation software, GastroPlusTM.

This expanded partnership brings greater understanding of a compound’s potential exposure in both preclinical and clinical studies. Jointly they are already working in collaboration on a number of client projects using these combined technologies.

Overcoming the challenges

One of the largest challenges of bringing new medicines to market is reducing the rates of attrition due to lack of efficacy and safety profile of a compound, whilst managing costs. Attrition in the pharma industry remains high at around 90% from Phase 1 to launch of a novel drug.

About GastroPlus™

GastroPlusTM is a software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data to be integrated within the context of a virtual animal or a human model. Having this in-silico understanding can help make faster and more informed development decisions. It has been identified as the number one commercially ranked program for in vitro – in vivo extrapolation and has been the focus of several publications from the FDA.

Influencing drug development projects

Graham Trevitt, Director of DMPK, Consultancy, Modelling & Simulation at XenoGesis said: “For researchers, it is difficult to measure everything as a project winds its way through the R&D process. Data that is generated is often difficult to interpret, yet expected to inform speedy decisions that influence the drug development project. Making the wrong decision can be costly in terms of time and money.”

He continues, “GastroPlus™ gives our clients access to a gold standard tool that will help them understand the potential exposure of a compound in both pre-clinical and clinical studies. By integrating PK-PD data, this allows prediction of efficacious doses. In turn this can save time and money in our clients’ drug discovery projects.”

Richard Weaver, Managing Director of XenoGesis added, “We continue to invest in the best technology and systems to support our clients and help them to achieve greater success in their drug discovery projects. We work closely with our partners at Juniper Pharma Services, to bring GastroPlus™ and Enabling Technologies Rapid Screen™ together and are already working in collaboration on a number of client projects using these combined technologies.”

Claire Madden-Smith, SVP at Juniper Pharma Services, said: “We are delighted to be further strengthening our relationship with XenoGesis with their addition of GastroPlusTM. Our combined offering provides our clients unique access to development and DMPK expertise that is truly advancing programmes smartly and rapidly.”